



Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences

SAN DIEGO, April 27, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) announced today that data from clinical trials of its investigational product candidate, Acetavance(TM) (intravenous acetaminophen), will be presented at the American Society of Regional Anesthesia and Pain Medicine (ASRA) 34th Annual Regional Anesthesia Meeting in Phoenix, Arizona on April 30, 2009 and at the Society of Hospital Medicine (SHM) Annual Meeting in Chicago, Illinois on May 16, 2009.

At the ASRA meeting, data from three completed clinical trials of Acetavance will be presented in poster presentations, as follows:

- "A Phase III, Multi-Center, Randomized, Double-blind, Placebo-Controlled 24 Hour Study of the Efficacy and Safety of Intravenous Acetaminophen in Abdominal Laparoscopic Surgery" (Study 304; abstract number 97)
- "A Phase III, Multicenter, Open-label, Prospective, Repeated Dose, Multi Day Randomized Controlled Study of the Safety of IV Acetaminophen in Adults" (Study 351; abstract number 96)
- "Pediatric Safety of Repeated Doses of IV Acetaminophen" (Study 352; abstract number 58)

Data from two other completed clinical trials of Acetavance will be presented in poster presentations at the SHM meeting, as follows:

- "Randomized Study of the Efficacy and Safety of IV Acetaminophen Compared to Placebo for the Treatment of Fever" (Study 302; abstract number 85)
- "Randomized Study of the Efficacy and Safety of IV Acetaminophen Compared to Oral Acetaminophen for the Treatment of Fever" (Study 303; abstract number 84)

Top line data from each of these clinical trials has been previously disclosed by Cadence, with the exception of data from Study 352, which was recently completed.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company is currently developing Acetavance(TM) (intravenous acetaminophen), its product candidate for the treatment of acute pain and fever. For more information about Cadence's pipeline, visit www.cadencepharm.com.

Cadence(TM) and Acetavance(TM) are trademarks of Cadence Pharmaceuticals, Inc.

Contacts: William R. LaRue
SVP & Chief Financial Officer
Cadence Pharmaceuticals, Inc.
858-436-1400

SOURCE Cadence Pharmaceuticals, Inc.

<http://www.cadencepharm.com>

